Real-World Analysis of the EGFR Mutation Test in Tissue and Plasma Samples from Non-Small Cell Lung Cancer

被引:4
|
作者
Lee, Hyunwoo [1 ]
Han, Joungho [1 ]
Choi, Yoon-La [1 ,2 ]
机构
[1] Sungkyunkwan Univ, Samsung Med Ctr, Dept Pathol & Translat Genom, Sch Med, Seoul 06351, South Korea
[2] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul 06351, South Korea
基金
新加坡国家研究基金会;
关键词
lung neoplasms; non-small cell lung cancer; circulating tumor DNA; epidermal growth factor receptor; prognosis; ADENOCARCINOMA HISTOLOGY; MOLECULAR EPIDEMIOLOGY; OSIMERTINIB; ERLOTINIB; AFATINIB;
D O I
10.3390/diagnostics11091695
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Molecular evaluation of EGFR mutation is indispensable in treating non-small cell lung cancer (NSCLC). We compared the results of EGFR analysis using tissue DNA (tDNA) and circulating tumor (ctDNA) to evaluate the feasibility of plasma as an effective material for detecting EGFR mutation and the reliability of ctDNA analysis in real-world practice settings. We enrolled 554 NSCLC cases who had undergone ctDNA EGFR analysis between January 2019 and March 2020. EGFR mutations were detected in 240 (57.3%) of the 421 cases with EGFR mutations confirmed by tDNA analysis. In multivariate analysis, the size of the largest tumor deposits, disease progression, M stage, the detectable amount of tumor tissue with EGFR mutation in distant metastasis, liver metastasis, pleural seeding, and bone metastasis (p < 0.05) were identified as independent factors affecting the detection rate of EGFR mutations in ctDNA. Survival analysis revealed ctDNA status and M stage (p < 0.001) to be independent predictors of overall survival in the multivariate analysis. Our study demonstrates that EGFR analysis using ctDNA is a useful clinical tool and can aid in therapeutic decisions in real-world practical settings. However, clinicians should be aware of the possibility of false negatives and confirm EGFR analysis using tDNA in certain situations.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
    Hong, Min Hee
    Kim, Hye Ryun
    Ahn, Beung-Chul
    Heo, Su Jin
    Kim, Jee Hung
    Cho, Byoung Chul
    [J]. YONSEI MEDICAL JOURNAL, 2019, 60 (06) : 525 - 534
  • [2] Real-world analysis of the EGFR mutation detection in plasma ctDNA from patients with non-small cell lung cancer.
    Long, Chaolian
    Li, Kun
    Liu, Zichen
    Zhang, Nana
    Xing, Xuya
    Xu, Liming
    Gai, Fei
    Che, Nanying
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Real-world analysis of the EGFR T790M mutation in plasma and tissue biopsy from advanced non-small cell lung cancer
    Lee, Eun Hye
    Kwak, Se Hyun
    Kim, Chi Young
    Lee, Sang Hoon
    Kim, Eun Young
    Chang, Yoon Soo
    [J]. RESPIROLOGY, 2023, 28 : 99 - 100
  • [4] Real-world analysis of the prognostic value of EGFR mutation detection in plasma ctDNA from patients with advanced non-small cell lung cancer
    Long, Chaolian
    Li, Kun
    Liu, Zichen
    Zhang, Nana
    Xing, Xuya
    Xu, Liming
    Gai, Fei
    Che, Nanying
    [J]. CANCER MEDICINE, 2023, 12 (07): : 7982 - 7991
  • [5] EMERGENT THERAPIES AND EGFR MUTATION TESTING IN NON-SMALL CELL LUNG CANCER: REAL-WORLD PRACTICES
    Chen, L.
    Herrington, J. D.
    Godley, P. J.
    Rao, A.
    Henderson, S. M.
    [J]. VALUE IN HEALTH, 2018, 21 : S41 - S41
  • [6] DIAGNOSTIC VALUE OF EGFR MUTATION TEST FROM PLASMA (CTDNA) COMPARED WITH TISSUE SAMPLE ON NON-SMALL CELL LUNG CANCER
    Herman, Herman
    Pratiwi, Suryanti Dwi
    Putu, Ngakan
    Putra, Parsama
    [J]. RESPIROLOGY, 2019, 24 : 54 - 54
  • [7] Real-world data analysis of comprehensive genomic profiling using plasma samples from non-small cell lung cancer patients
    Morishita, Momoko
    Fujii, Koki
    Ueki, Michiko
    Ikushima, Hiroaki
    Isago, Hideaki
    Watanabe, Kousuke
    Oda, Katsutoshi
    Kage, Hidenori
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [8] REAL-WORLD EFFECTIVENESS OF OSIMERTINIB IN NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: SYSTEMATIC REVIEW AND META-ANALYSIS
    Almutairi, A.
    Alkhatib, N.
    Maghaireh, M.
    Halloush, S.
    Rashdan, O.
    Manasrah, A.
    Abraham, I
    Almaaytah, A.
    Abumansour, H.
    Saleh, M.
    Khassawaneh, A.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S188 - S188
  • [9] Use of the Idylla EGFR Mutation Test for Variant Detection in Non-Small Cell Lung Cancer Samples
    Hawkins, Paul
    Stevenson, Tracey
    Powari, Manish
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2021, 156 (04) : 653 - 660
  • [10] Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101)
    Tsuji, Kosuke
    Mizugaki, Hidenori
    Yokoo, Keiki
    Kobayashi, Maki
    Kawashima, Yosuke
    Kimura, Nozomu
    Yokouchi, Hiroshi
    Kikuchi, Hajime
    Sumi, Toshiyuki
    Kawai, Yasutaka
    Kobashi, Kenta
    Morita, Ryo
    Ito, Kenichiro
    Kitamura, Yasuo
    Minemura, Hiroyuki
    Nakamura, Keiichi
    Aso, Mari
    Honjo, Osamu
    Tanaka, Hisashi
    Takashina, Taichi
    Tsurumi, Kyoji
    Sugisaka, Jun
    Tsukita, Yoko
    Konno, Satoshi
    Oizumi, Satoshi
    [J]. CANCER SCIENCE, 2024, 115 (04) : 1273 - 1282